miR Scientific Canada Inc. is the Canadian subsidiary of miR Scientific LLC. miR Scientific LLC is a precision molecular bioscience company that creates and delivers scalable breakthrough technologies for the provision of accessible diagnostic, prognostic, monitoring and companion products and services for large at-risk cancer populations. miR's pipeline of products includes the Prostate Cancer Sentinel Assay Test(tm), a urine-based liquid biopsy test with unprecedented accuracy that has the potential to save thousands of men from suffering possible severe side effects of unnecessary prostate cancer treatments. The Company was incorporated in 2014 as a commercial spin-out from the State of New York University at Albany's Cancer Research Center and currently has operations in Rensselaer, New York City, Israel and Canada.